This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated six-month revenue up 6.6%, profit after tax up 4.5%; quarter split absent
MEDISTEP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
No consolidated quarter figures are given for the six months ended 30 September 2026; quarter comparison is unavailable. For the consolidated six-month period, revenue was Rs 3,737.34 lakh versus Rs 3,506.88 lakh, up 6.6%; profit after tax was Rs 310.34 lakh versus Rs 297.09 lakh, up 4.5%. Operating cash flow was positive at Rs 86.18 lakh. Earnings per share fell to Rs 2.18 from Rs 2.61. The review found no issue; prior figures were regrouped.
Profit growth and cash flow are supportive, but lower EPS and no quarterly split temper the outlook. Borrowings are modest at 0.13 times equity.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹37.37 Cr | ₹35.07 Cr | +6.6% |
| Operating profit | ₹4.18 Cr | ₹3.97 Cr | +5.4% |
| Profit after tax | ₹3.13 Cr | — | — |
| EBITDA margin | 11.8% | — | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.